STONY BROOK N.Y. (September 18, 2017) – Applied DNA Sciences, Inc. (“Applied DNA,” “the Company,” NASDAQ: APDN), today announced that it has filed a Registration Statement with the Securities and Exchange Commission (the “Registration Statement”) with respect to the sale by certain selling security holders of common stock to be received upon exercise of warrants previously sold by the Company in 2014. The Registration Statement is being filed to update a registration statement originally filed in 2014. The warrants to purchase 3,215,590 shares have an exercise price of $3.50 and are listed on NASDAQ under the symbol APDNW. In addition, the Registration Statement relates to the sale of common stock to be received by certain selling security holders upon the exercise of warrants sold to investors in a private placement in 2015 and issued to placement agents and underwriters of various offerings by the Company in 2011, 2014, 2015 and 2016. These warrants to purchase an aggregate of 1,727,630 shares have exercise prices ranging from $2.53 to $4.30.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When available, a written prospectus may be obtained from Applied DNA Sciences, Inc. at 50 Health Sciences Drive, Stony Brook, New York 11790, Attn: Beth Jantzen.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT™” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopiable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May 11, 2017 and August 10, 2017, which are available at www.sec.gov. APDN, undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777
web: www.adnas.com
twitter: @APDN